221 related articles for article (PubMed ID: 2610178)
1. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
2. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
[TBL] [Abstract][Full Text] [Related]
3. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
4. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
Merrick MV; Ding CL; Chisholm GD; Elton RA
Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
[TBL] [Abstract][Full Text] [Related]
6. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
[No Abstract] [Full Text] [Related]
7. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
9. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
[TBL] [Abstract][Full Text] [Related]
10. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
Nakashima J
Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
[No Abstract] [Full Text] [Related]
11. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
12. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
Kida T; Higuchi Y
Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
[TBL] [Abstract][Full Text] [Related]
13. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
Nemoto S; Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
[No Abstract] [Full Text] [Related]
14. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
Gerber G; Chodak GW
Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
[TBL] [Abstract][Full Text] [Related]
15. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.
Noguchi M; Kikuchi H; Ishibashi M; Noda S
Br J Cancer; 2003 Jan; 88(2):195-201. PubMed ID: 12610502
[TBL] [Abstract][Full Text] [Related]
16. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
[TBL] [Abstract][Full Text] [Related]
17. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.
Takahashi Y; Yoshimura M; Suzuki K; Hashimoto T; Hirose H; Uchida K; Inoue S; Koizumi K; Tokuuye K
Ann Nucl Med; 2012 Aug; 26(7):586-93. PubMed ID: 22744807
[TBL] [Abstract][Full Text] [Related]
18. [Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival].
Lobo G; Ladrón de Guevara D; Salgado G; Donoso G; Bagus F
Rev Med Chil; 1999 Feb; 127(2):181-8. PubMed ID: 10436698
[TBL] [Abstract][Full Text] [Related]
19. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
20. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
